Estepan Michael Ian's Insider Trades & SAST Disclosures
Estepan Michael Ian's most recent trade in Sarepta Therapeutics Inc was a trade of 16,644 Stock Options (right to buy) done . Disclosure was reported to the exchange on March 7, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Estepan Michael Ian.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2025 | 16,644 | 16,644 | - | - | Stock Options (right to buy) | |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2025 | 8,276 | 62,612 (0%) | 0% | - | Common Stock | |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2025 | 5,500 | 0 | - | - | Performance Stock Units | |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2025 | 5,500 | 58,277 (0%) | 0% | - | Common Stock | |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 100.13 per share. | 07 Mar 2025 | 2,890 | 54,336 (0%) | 0% | 100.1 | 289,376 | Common Stock |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 100.13 per share. | 07 Mar 2025 | 1,051 | 57,226 (0%) | 0% | 100.1 | 105,237 | Common Stock |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 17,500 | 62,456 (0%) | 0% | - | Common Stock | |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 17,500 | 0 | - | - | Performance Stock Units | |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.70 per share. | 06 Mar 2025 | 9,094 | 52,777 (0%) | 0% | 103.7 | 943,048 | Common Stock |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.70 per share. | 06 Mar 2025 | 585 | 61,871 (0%) | 0% | 103.7 | 60,665 | Common Stock |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 101.34 per share. | 04 Mar 2025 | 1,370 | 44,956 (0%) | 0% | 101.3 | 138,836 | Common Stock |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.77 per share. | 03 Mar 2025 | 557 | 46,326 (0%) | 0% | 103.8 | 57,800 | Common Stock |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 3,500 | 17,500 | - | - | Performance Restricted Stock Units | |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.00 per share. | 29 Jan 2025 | 14,267 | 47,963 (0%) | 0% | 12 | 171,204 | Common Stock |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2025 | 14,267 | 0 | - | - | Stock Option (right to buy) | |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 117.51 per share. | 29 Jan 2025 | 2,613 | 46,883 (0%) | 0% | 117.5 | 307,054 | Common Stock |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.00 per share. | 29 Jan 2025 | 1,533 | 49,496 (0%) | 0% | 12 | 18,396 | Common Stock |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2025 | 1,533 | 0 | - | - | Stock Option (right to buy) | |
| Sarepta Therapeutics Inc | Estepan Michael Ian | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 27 Dec 2024 | 250 | 33,696 (0%) | 0% | 0 | Common Stock | |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 137.36 per share. | 30 Aug 2024 | 5,985 | 33,946 (0%) | 0% | 137.4 | 822,100 | Common Stock |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2024 | 6,250 | 0 | - | - | Performance Stock Units | |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2024 | 6,250 | 42,414 (0%) | 0% | - | Common Stock | |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 6,250 | 6,250 | - | - | Performance Stock Units | |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 5,500 | 5,500 | - | - | Performance Stock Units | |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 164.64 per share. | 21 Jun 2024 | 2,483 | 39,931 (0%) | 0% | 164.6 | 408,801 | Common Stock |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 123.14 per share. | 07 Mar 2024 | 1,035 | 36,164 (0%) | 0% | 123.1 | 127,450 | Common Stock |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 120.49 per share. | 07 Mar 2024 | 526 | 37,199 (0%) | 0% | 120.5 | 63,378 | Common Stock |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 125.32 per share. | 04 Mar 2024 | 1,389 | 37,725 (0%) | 0% | 125.3 | 174,069 | Common Stock |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 6,000 | 40,314 (0%) | 0% | 0 | Common Stock | |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 128.30 per share. | 01 Mar 2024 | 1,200 | 39,114 (0%) | 0% | 128.3 | 153,960 | Common Stock |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 126.19 per share. | 01 Mar 2024 | 365 | 34,314 (0%) | 0% | 126.2 | 46,059 | Common Stock |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 153.19 per share. | 08 Mar 2023 | 744 | 34,679 (0%) | 0% | 153.2 | 113,973 | Common Stock |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 27,000 | 27,000 | - | - | Stock Option (right to buy) | |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 4,500 | 35,423 (0%) | 0% | 0 | Common Stock | |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.21 per share. | 06 Mar 2023 | 1,370 | 30,923 (0%) | 0% | 157.2 | 215,378 | Common Stock |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 147.57 per share. | 01 Mar 2023 | 378 | 32,293 (0%) | 0% | 147.6 | 55,781 | Common Stock |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 48,000 | 48,000 | - | - | Stock Option (right to sell) | |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 8,000 | 32,671 (0%) | 0% | 0 | Common Stock | |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.20 per share. | 04 Mar 2022 | 1,308 | 25,069 (0%) | 0% | 79.2 | 103,594 | Common Stock |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.36 per share. | 04 Mar 2022 | 398 | 24,671 (0%) | 0% | 79.4 | 31,585 | Common Stock |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.05 per share. | 01 Mar 2022 | 376 | 26,377 (0%) | 0% | 75.1 | 28,219 | Common Stock |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.29 per share. | 08 Sep 2021 | 1,623 | 26,753 (0%) | 0% | 78.3 | 127,065 | Common Stock |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2021 | 15,000 | 28,723 (0%) | 0% | 0 | Common Stock | |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 84.65 per share. | 28 Feb 2021 | 347 | 28,376 (0%) | 0% | 84.7 | 29,374 | Common Stock |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 86.97 per share. | 28 Feb 2021 | 319 | 13,723 (0%) | 0% | 87.0 | 27,743 | Common Stock |
| Sarepta Therapeutics Inc | Ian Michael Estepan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2020 | 25,000 | 25,000 | - | - | Stock option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges